Results 41 to 50 of about 3,260 (169)

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Eltrombopag in Good’s Syndrome

Case Reports in Hematology, 2014
Good’s syndrome is a rare acquired immunodeficiency associated with thymoma. Eltrombopag is a thrombopoietin receptor agonist and has been shown to be a valuable supplement to the treatment of several types of refractory cytopenias.
Håvard Anton Kristiansen, Signe Spetalen, Yngvar Fløisand, Dag Heldal   +3 more
doaj   +1 more source

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial

eJHaem, 2023
Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux   +10 more
doaj   +1 more source

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease

Journal of Blood Medicine, 2019
Abraham Z Cheloff, Hanny Al-Samkari Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USACorrespondence: Hanny Al-SamkariDivision of Hematology, Massachusetts General Hospital, Suite 118, Room 112, Zero Emerson ...
Cheloff AZ, Al-Samkari H
doaj  

Real-world experience with romiplostim in the management of primary immune thrombocytopenia in Iraqi adult patients

Iraqi Journal of Hematology
BACKGROUND: Low platelet counts resulting from increased platelet breakdown and poor platelet generation are the hallmarks of immune thrombocytopenia (ITP), an autoimmune illness.
Alaadin Sahham Naji, Alhan A. Alkhalidi, Luma Essa Hammodi, Ahmed Mjali   +3 more
doaj   +1 more source

Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis

Haematologica, 2018
Corticosteroids such as prednisolone and dexamethasone have been established as up-front therapy for the treatment of newly diagnosed immune thrombocytopenia.
Yasuyuki Arai, Tomoyasu Jo, Hiroyuki Matsui, Tadakazu Kondo, Akifumi Takaori-Kondo   +4 more
doaj   +1 more source

Thrombocytopenia in Pregnancy: A 5‐Year Analysis of Characteristics and Practices From a Tertiary Academic Center

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Moderate‐to‐severe thrombocytopenia (platelet count < 100 × 109/L) occurs in fewer than 1% of pregnancies, posing management challenges, particularly surrounding eligibility for neuraxial anesthesia. Although recent anesthesia guidelines recommend a platelet threshold ≥ 70 × 109/L, outcomes data applying these recommendations in ...
Mackenzie E. Lemieux, Ming Y. Lim
wiley   +1 more source

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

American Journal of Hematology, Volume 101, Issue 9, Page 2393-2411, September 2026.
ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley   +1 more source

Interstitial 11q Deletions and Terminal 11q Duplications Cause a Bleeding Tendency due to Platelet Dysfunction That Is Similar to 11q Deletions Causing Jacobsen Syndrome

European Journal of Haematology, Volume 117, Issue 3, Page 662-672, September 2026.
ABSTRACT Introduction Jacobsen syndrome, resulting from a terminal deletion of chromosome 11 (11q), may lead to an increased bleeding tendency due to low platelet counts or platelet dysfunction. Currently, information on bleeding tendency and platelet function in patients with nonterminal 11q‐aberrations such as larger deletions, interstitial 11q ...
Elise J. Huisman, Virgil A. S. H. Dalm, Marieke Joosten, Frans J. Smiers, Leendert Porcelijn, Arjan Hoogendijk, Hans Janssen, Nicole N. van der Wel, Idske C. L. Kremer Hovinga, Masja de Haas, Marjon H. Cnossen   +10 more
wiley   +1 more source

Successful avatrombopag combined with cyclosporine treatment for carboplatin/pegylated liposomal doxorubicin/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report

Frontiers in Oncology
Carboplatin/pegylated liposomal doxorubicin/bevacizumab is an accepted standard anti-cancer treatment option for recurrent ovarian cancer. However, the occurrence of adverse events associated with this therapeutic regimen limits its continued clinical ...
Weikang Meng, Jinsheng Hua, Jiabing Wang
doaj   +1 more source